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cientiﬁc Comment
tility of the p53 mutant protein in patients with
ow-risk myelodysplastic syndrome
avid C. Yaoa,b, Marcos de Limaa,b,∗University Hospitals Case Medical Center, Cleveland, United States
elan
ization of the role of p53 in a larger cohort of low-risk MDSSeidman Cancer Center and Case Western Reserve University, Clev
n this issue of the Revista Brasileira de Hematologia e
emoterapia, Duarte et al.1 present data on the role of p53
rotein expression and prognosis of patients with low-risk
yelodysplastic syndrome (MDS). In a cohort of 38 patients,
he authors demonstrated an association betweenmutant p53
rotein expression and shortened survival.
MDS is a clinically heterogeneous disorder.2 Patients with
his condition demonstrate clonal hematopoietic expansion,
ytopenias, myelodysplasia, ineffective hematopoiesis and
n increased propensity to develop acute myeloid leukemia.
ot surprisingly, prognosis is related to severity of cytopenias,
resence of cytogenetic abnormalities and clonal evolution
emonstrated by blast counts, and other ‘traditional’ progno-
tic elements. There is heterogeneity even among patients
iagnosed with lower-risk disease, since a subset of these
atients have more aggressive disease. Recent efforts have
emonstrated that several molecular parameters linked to
he pathophysiology of MDS may affect overall survival.3,4
hus, identiﬁcation of additional prognosticators that more
ccurately characterize subgroups and their outcomes are
ssential.
Current understandingof thepathophysiology ofMDS indi-
ates that there are founding mutations in a hematopoietic
tem cell that ultimately offer a survival advantage to the
ffected cell(s). These mutations occur in genes encoding
rotein products that are involved typically in either RNA
plicing or DNA methylation, which in turn leads to genomic
5nstability and further mutations. The survival advantage in
utated cells usually leads to a dominant bone marrow pro-
enitor clone. This clone can subsequently acquire additional
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driver mutations that lead to the development of multiple
subclonal populations. The accumulation and combination
of these genetic lesions likely contribute to the phenotypes
observed in MDS patients. TP53 gene mutations are partic-
ularly interesting given the fact that its protein product has
tumor suppression activity.
TP53 encodes a cytoplasmic protein p53 that regulates cell
growth and death. Mutations have been identiﬁed in a variety
of cancers.6 In MDS, TP53 mutations have been found mainly
in intermediate- to high-risk patients. Patients often present
with complex cytogenetic abnormalities, severe thrombocy-
topenia, increased risk of leukemia progression, and have
shorter survival.7,8 While it has been well documented that
genetic lesions in TP53 carry an independent poor prognostic
value, mostly amongst advanced stage patients,9,10 the role of
TP53 mutations in low-risk MDS remains unclear. Duarte et al.
examined whether intracellular accumulation of mutant p53
correlates with clinical characteristics and prognosis among
38 patients with low-risk MDS (deﬁned by current scoring
system).1 Patients with mutant p53 were older, anemic and
leukopenic at the time of diagnosis, and had a shorter median
survival compared to those carrying wild-type p53.
Duarte et al. concluded that molecular identiﬁcation of
mutant p53 contributes to risk stratiﬁcation of patients with
low-risk MDS, which may alter the treatment approach.1 The
authors provide a compelling argument for further character-100 Euclid Avenue, Cleveland, OH 44106, United States.
patients.
Interpreting p53 mutation role in MDS is not a trivial
task, however, since there are often complicating interactions
e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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with other intracellular regulators.11 A recent effort to
characterize genetic lesions in MDS showed that each
patient frequently harbors mutations in multiple genes
simultaneously.8 In another study, mutations in genes ASXL1,
EZH2, RUNX1, NRAS and others were associated with shorter
overall survival in lower-risk MDS.12 Interestingly, interactions
among these gene products and p53 have been documented
extensively.13,14
Over the past 5–10 years a variety of technologies have
improved andenabledhigh-throughput analysis of entireMDS
genomes, leading to the identiﬁcation of several new poten-
tially targetable genes implicated in MDS pathogenesis. The
challenge is how to incorporate these into new prognostic sys-
tems. In addition, it is expected that these approaches will
lead to therapeutic insights that are desperately needed for
MDS patients.
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